Moderna, Merck begin late-stage study for mRNA cancer therapy

[December 11, 2023]  (Reuters) - Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration